Differences in Metabolic Profiles of Healthy Dogs Fed a High-Fat vs. a High-Starch Diet

Yang Lyu 1, Daisy Liu 1, Patrick Nguyen 2, Iain Peters 3, Romy M. Heilmann 4, Veerle Fievez 5, Lieselot Y. Hemeryck*† and Myriam Hesta*†

1 ECAN Equine and Companion Animal Nutrition, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 2 Nutrition, Physiopathology and Pharmacology Unit, National College of Veterinary Medicine, Food Science and Engineering, Nantes, France, 3 SYNLAB VPG, Exeter Science Park, Exeter, United Kingdom, 4 Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, United States, 5 Department of Animal Sciences and Aquatic Ecology, Faculty of Bioscience Engineering, Ghent, Belgium, 6 Laboratory of Chemical Analysis, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

Obesity is a common problem in dogs and overconsumption of energy-rich foods is a key factor. This study compared the inflammatory response and fecal metabolome of dogs fed a high-fat vs. a high-starch diet. Ten healthy lean adult beagles were equally allocated into two groups in a cross-over design. Each group received two diets in which fat (horse fat) and starch (pregelatinized corn starch) were exchanged in an isocaloric way to compare high fat vs. high starch. There was a tendency to increase the glucose and glycine concentrations and the glucose/insulin ratio in the blood in dogs fed with the high-fat diet, whereas there was a decrease in the level of Non-esterified fatty acids and a tendency to decrease the alanine level in dogs fed with the high-starch diet. Untargeted analysis of the fecal metabolome revealed 10 annotated metabolites of interest, including L-methionine, which showed a higher abundance in dogs fed the high-starch diet.

The obtained results indicate that a high-starch diet, compared to a high-fat diet, may promote lipid metabolism, anti-oxidative effects, protein biosynthesis and catabolism, mucosal barrier function, and immunomodulation in healthy lean dogs.

Keywords: starch, fat, fecal metabolome, obesity, dogs

INTRODUCTION

Obesity is one of the largest health challenges nowadays in dogs. Studies report a prevalence of canine overweight and obesity ranging from 34 to 60% (1–3). Obesity in dogs has been linked to not only a decreased vitality, emotional wellbeing, and longevity but also an increased risk of certain health issues such as insulin resistance, hypertension, cardiovascular disease, and osteoarthritis (4, 5). While multiple molecular mechanisms might link obesity to its complications, inflammation is a common feature that has been implicated in the pathophysiology of many obesity-associated disorders (6). Similarly to these findings in humans, it has been revealed that obese and overweight dogs showed a higher inflammatory state (7), as indicated by increased concentrations of serum interleukin-6 (IL-6) (7), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) (8).
The increase in adiposity is often attributed to high dietary fat intake (9). Many studies have shown that high-fat diets (>30% of energy from fat) can easily induce obesity in humans (10, 11), mice (12, 13), and dogs (14, 15). When the average amount of fat in the diet increases, the incidence of obesity also rises (11, 12). Furthermore, in mice and humans, consumption of high-fat diets leads to alterations in the composition and function of the gut microbiota, promoting metabolic endotoxemia and triggering an inflammatory response (13, 16). In dogs, feeding a high-fat diet is associated with insulin resistance (17), reduced brain insulin transport (14), decreased microbiota α-diversity (15), and reduced abundance of Prevotella, Solobacterium, and Coprobucaillus (18). However, the majority of studies on the intake and possible adverse health effects of a high-fat diet in dogs focused on increased inflammation and alterations in the gut microbiome, but no study so far has investigated the effect of a high-fat diet on the gut metabolome.

Starch is the most abundant dietary nutrient globally, and provides energy to a rapidly growing human population (19), and is also a main nutritional source for pet dogs (20). However, this highly digestible energy source could also lead to nutrition-related health problems. Studies have suggested that typical starch-rich diets can also contribute to obesity (19, 21), hyperglycaemia (21), pathogenesis and difficulty of managing type 2 diabetes mellitus (22), as well as cardiovascular disease (23). In dogs, nutritional research on dietary starch mainly concerns its digestibility and fermentation, but not the effect of high-starch diets on metabolic changes and inflammatory responses.

Metabolomics is the study of all small molecules detectable in a biological sample. It provides information on subclinical metabolic alterations associated with (patho)physiological changes and disease outcomes (24). Metabolome analysis has revealed previously unknown alterations in amino acid, lipid, and carbohydrate metabolism across species, with underlying links to several conditions like obesity, inflammation, and oxidative stress (25). Metabolomics is rather emerging in canine nutrition, with current research being limited to study the metabolomic profile in the healthy vs. obese or overweight dogs (26), and in dogs fed with different protein levels (27), with far more pending to be explored. The present study aimed to compare the inflammatory status and fecal metabolome of lean dogs fed a high-fat vs. a high-starch diet, providing new insights and basis for a theoretical framework for high-fat vs. high-starch induced metabolic and inflammatory effects in relation to obesity.

**MATERIALS AND METHODS**

**Animals and Experimental Design**

Ten healthy adult research beagles of ideal body weight (BW) and condition (4 intact females, 3 intact males and 3 neutered males; 4.2 ± 2.6 y; 10.5 ± 1.2 kg; body condition score (BCS) 4–5/9) were equally allocated into two groups in a cross-over study design with two periods of 6 weeks each. All dogs were housed individually and under a 12-h light and 12-dark cycle with a room temperature of 17°C. Prior to the study, a commercial standard diet (Hill's Science Plan Advanced Fitness; Hill's Pet Nutrition, Inc., Topeka, KS, USA) mixed with experimental diets was fed to the dogs for 1 week adaption —75% standard with 25% experimental diets for 3 days, 50% of each for 2 days, and 75% experimental with 25% standard diets for 2 days. During the first period of the study (P1), five dogs in group A were fed a high-starch (HS; pregelatinized corn starch; ∼63.5% carbohydrate and 9.4% fat) diet and five dogs in group B were fed a high-fat (HF; horse fat; ∼12.9% carbohydrate and 46.9% fat) diet. After P1, a mixture of two experimental diets was fed to the dogs for one-week transition—group A: 75% HS with 25% HF diet for 3 days, 50% of each for 2 days, and 75% HS with 75% HF for 2 days; same proportion but reverse diets for group B. Experimental diets were then completely switched during the second period of the study (P2).

Diets were formulated to be isonitrogenous on energy basis, so that for a given energy allocation the protein intake was similar regardless of the diet. The formulation of both diets is presented in Table 1. The HF and HS diet contained 18.2 g crude fat, 13.9 g crude protein, and 5.0 g nitrogen-free extract per MJ, and 5.2 g crude fat, 13.1 g crude protein, and 35.0 g nitrogen-free extract per MJ, respectively. Dogs were fed once a day at 10:00 a.m., and had free access to water. Body weight and BCS were assessed weekly. Food intake was recorded daily, and the amount was adjusted weekly to maintain a stable body weight, if needed.

All samples were collected at the end of each study period. Fasting blood samples (∼30 mL) were drawn from the jugular vein. An aliquot of ∼4 mL was collected in PAXgene Blood RNA tubes (PreAnalytix X GmbH, Erembodegem, Belgium) to analyse mRNA expression of TLR-4, CD14, IL-10, IL-18, IL-1β, IL-1RA, IL-8, and TNF-α. Serum and plasma for assessing mRNA expression, acylcarnitine and amino acid profiles were obtained by centrifuging blood at 2000 x g for 15 min at 4°C, which was stored at −20°C until analysis. Fresh fecal samples (∼10 g) were collected within 10 min after spontaneous defaecation. The samples were scored for fecal consistency (1 = watery liquid feces that can be poured; 2 = soft, unformed stool that assumes the shape of the recipient; 3 = soft, formed, moist stool; 4 = hard, formed, dry stool; 5 = hard, dry stool), and fecal pH was measured with a portable pH meter (Hanna Instruments Ltd., Temse, Belgium). An aliquot of ± 2 g was placed into a sterile plastic tube, frozen immediately on dry ice, lyophilized as soon as possible, and stored at −80°C in preparation of metabolomic

**TABLE 1** Formulation of the diets (g/kg).

| Item                      | High Starch diet (HS) | High Fat diet (HF) |
|---------------------------|-----------------------|-------------------|
| Horse hearts              | 701.5                 | 827.6             |
| Corn starch (pregelatinized) | 287.6              | 0.0               |
| Corn oil                  | 3.9                   | 4.6               |
| Horse fat                 | 1.4                   | 161.4             |
| Premix                    | 5.6                   | 6.4               |
| KJ/100g Dry matter        | 1,811                 | 2,579             |
analysis. The remainder of the fecal sample was stored at −20°C for chemical analyses.

**Analytical Methods**

Body composition was determined by the deuterium dilution method using Fourier-transform infrared spectroscopy as described by (28).

Proximate analysis was performed on the diets using standard methods, ISO 1442:1997 for dry matter, ISO 936:1998 for crude ash, Kjeldahl nitrogen (6.25 × N, ISO 5893–1, 2005) for dietary crude protein, and ISO 5498:1981 for crude fiber. Nitrogen-free extract was calculated by subtracting crude ash, crude protein, crude fat, and crude fiber from the dry matter content. A Total Dietary Fiber Assay Kit (Sigma–Aldrich Co., Overijse, Belgium) was used to determine total dietary fiber and insoluble dietary fiber using procedures based on a combination of enzymatic and gravimetric methods (29). Soluble dietary fiber was calculated by subtracting insoluble dietary fiber from total dietary fiber.

Serum concentrations of glucose, triglyceride, cholesterol, and total protein were determined using the Architect C16000 analyser (Abbott Max-Planck-Ring, Wiesbaden, Germany). Fibrinogen concentration was determined using the Sysmex CS-5100 analyser (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany), insulin concentration was measured by a commercially available kit (INS-Imra, DIAsource ImmunoAssays S.A., Louvain-la-Neuve, Belgium), and the insulin-to-glucose ratio was calculated as described in German et al., (30) to assess insulin sensitivity. Serum leptin concentration was measured using a validated, commercially available canine ELISA kit (Millipore Corp., Billerica, MA, USA) following the manufacturer’s instructions. Serum Non-esterfified fatty acids (NEFA) concentrations were analyzed by spectrophotometry (EZ Read 400 Microplate Reader, Biochrom Ltd., Cambridge, United Kingdom). Free carnitine, acylcarnitine and amino acid profiles were determined on lithium-heparin plasma by quantitative electrospray tandem mass spectrometry as previously described (31, 32). Blood lipopolysaccharides (LPS) concentrations were determined using a kinetic turbidimetric Limulus amoebocyte lysate (LAL) assay.

S100A12 concentration in serum and feces was determined by a species-specific ELISA (33). Fecal short-chain fatty acid [SCFA; i.e., acetate, propionate, butyrate, iso-butyrate, iso-valerate], and NH3 concentrations were determined first by extracting samples with 10% formic acid, containing 1 mg/ml 2-ethyl butyric acid as internal standard (3 g sample + 15 ml extraction fluid; shake for 5 min, centrifugate, and filtrate). The determination of respectively the volatile fatty acids and ammonia was carried out using gas chromatography as previously described (34, 35).

**mRNA Expression**

Total RNA was isolated from the PAXgene tubes using the PAXgene blood RNA kit (Qiagen, Manchester, UK) according to the manufacturer’s instructions. RNA concentration was measured using the Qubit RNA Assay Kit (Invitrogen, Paisley, Scotland). Primers and probes for the assay were designed using Primer 3 (www.genome.wi.mit.edu/cgi-bin/prime/primer3 www.cgl.) and M-Fold using the canine specific GenBank sequence for IL-1β (EU249360) and IL-1α (AF216526) as described previously (36). The assays for the 3 housekeeper genes (succinate dehydrogenase complex, subunit A [SDHA], TATA box binding protein [TBP], and tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein zeta polypeptide [YWAZ]) and the remaining genes (Supplementary Table 1) were the same as those used previously (37).

Synthesis of cDNA was carried out using the ImProm II Reverse Transcription System (Promega Corporation) with 500 ng of total RNA in a final volume of 20 µL. Quantitative PCR (qPCR) was performed using GoTaq Colorless Master Mix (Promega). Gene specific amplification was performed using 0.2 µM of each primer, 0.1 µM of the probe, ROX (1:5000, Invitrogen) and 5 µl of diluted cDNA in a final volume of 25 µL. Sample incubations were performed in an MxPro 3005P (Agilent) at 95°C for 2 min and then 45 cycles of 95°C for 10 sec and 60°C for 30 sec during which the fluorescence data were collected. Threshold values (Ct) for the samples were calculated using the MxPro qPCR software 4.1 (Agilent Technologies Co., Santa Clara, CA, USA). Relative copy number expression values were calculated for each sample and normalized against the housekeeper gene results using the qBase applet for Microsoft Excel (http://medgen.ugen.tu.com/qbase/) as described by Vandesompele et al. (38).

**Untargeted Metabolomics Analysis**

Freeze-dried fecal samples were subjected to generic extraction as optimized and described previously (39). Analysis of extracted fecal samples was performed using a Dionex UltiMate 3000 XRS UHPLC system (Thermo Fisher Scientific, San José, CA, USA) coupled to a Q-Exactive™ bench top Quadrupole-Orbitrap HRMS (Thermo Fisher Scientific, San José, CA, USA) (39, 40). Calibration of the Q-Exactive HRMS system was performed according to the instructions of the manufacturer. Internal (each 10 samples) and external QC (quality control) samples (pool of samples made from aliquots of the study samples) were analyzed prior to and after analysis of the samples to stabilize the system and monitor (and if needed, correct for) instrumental drift. Samples were analyzed in 1 batch, in a randomized order.

Raw data was Pre-processed using Sieve™ 2.1 (Thermo Fisher Scientific, San José, USA), as described by De Paepe et al. (40). Simca™ 13 (Umetrics AB, Umeå, Sweden) was used for multivariate statistical data processing. PCA-X and OPLS-DA modeling were performed following logarithmic data transformation and Pareto scaling, with further validation assessed by assessment of R2 and Q2 goodness (>0.5), permutation testing (n = 100) and cross-validated analysis of variance (CV-ANOVA, p < 0.05). Discriminative/predictive ions were selected based on their eccentric position in the S-plot [p (corrected) > 0.5] and a Variable Importance in Projection-score (VIP score) >2. Prediction of chemical formula was based on accurate mass and the full scan spectrum using Xcalibur™, i.e., obtained through calculation and evaluation of isotopic signature (carbon and sulfur) and allowing a mass mass deviation of 5 ppm. Putative identification was achieved using the Human Metabolome Database (HMDB), PubChem and Kyoto
Encyclopedia of Genes and Genomes (KEGG) databases (freely available online). A heatmap with dendrogram was generated using TBtools software (https://github.com/CJ-Chen/TBtools) to illustrate metabolite abundances and sample clustering.

**Statistical Analyses**

The metabolomic data were processed as described above. The effect of diets, periods and their interaction were analyzed by two-way ANOVA using MetaboAnalyst 3.0 software (McGill University, Canada).

To evaluate the effect of both the diet and the two-period dietary exchange, the remainder of the data was analyzed by Wilcoxon-Mann–Whitney test with diet, period and diet-period as factors and dog as random effect. These analyses were processed by R version 3.1.0 (The R Foundation for Statistical Computing) using the Coin package (version 1.0–23). Summary statistics were expressed as mean values ± SD. A p-value of < 0.05 was considered statistically significant and a p-value < 0.10 was considered as a significant trend. All p-values were corrected by the false discovery rate.

**RESULTS**

**Food Intake and Body Composition**

All dogs remained healthy throughout the study. All diets were well tolerated and did not affect the dogs’ food intake. Daily energy intakes did not differ between diets. There was no significant diet and period effect on BW and BCS at the end of each study period. Furthermore, neither diet nor period significantly affected the dogs’ absolute and relative body fat mass.

**Fecal Parameters**

There was no significant effect of diet and period on the fecal concentration of NH3, acetate, propionate, butyrate, isobutyrate, and iso-valerate. The diets also did not affect the fecal S100A12 concentrations, and no significant effect was observed on the fecal score and pH. These results are summarized in Supplementary Table 2.

**Blood Parameters**

Significant findings in blood parameters which did not significantly differ between diets or periods are available in Supplementary Table 3. A significant diet effect (p = 0.041) was observed for the pre-prandial NEFA concentration, with dogs being fed the high-starch diet showing a higher level of NEFA than dogs being fed the high-fat diet. Diet × period trends were observed for the plasma concentration of glycine (p = 0.077) and tyrosine (p = 0.058). Additionally, significant trends according to diet were observed for the plasma concentration of glucose (GLU; p = 0.054), glycine (Gly; p = 0.094), alanine (Ala; p = 0.089), and the ratio of glucose to insulin (GLU/INS; p = 0.063). More specifically, dogs on the high-fat diet displayed a trend for a decreased Ala concentration and an increased GLU concentration and GLU/INS ratio compared to dogs on the high-starch diet. Significant effects of period were also observed for the GLU/INS ratio (p = 0.036) and NEFA concentration (p = 0.042).

No significant dietary effect or trend was observed for LPS concentration, acylcarnitine profiles and mRNA expression levels in the blood (Supplementary Table 3).

**Fecal Metabolome**

A total of 4391 and 1934 ions were obtained in the positive and negative ionization mode, respectively. PCA-X score plots revealed good clustering of fecal samples according to diet in both positive and negative ionization mode (Supplementary Figure 1), as well as good clustering of QC samples. The characteristics of the OPLS-DA model (Supplementary Figure 2) were good to excellent: R² = 0.884 and Q² = 0.661 for the “positive” model and R² = 0.861 and Q² = 0.670 for the “negative” model, also obtaining successful cross-validation (CV-ANOVA with p < 0.01), as well as a valid permutation test. A total of 15 fat/starch associated metabolites could be retained (Supplementary Figure 3), with 5 unidentified metabolites and 9 putatively annotated metabolites. The identity of one metabolite marker; i.e., L-methionine, was confirmed by means of an analytical standard. An overview of the characteristics of the retrieved discriminative metabolites is presented in Table 3.

The results obtained for investigating the interaction among diet, period and their interaction are summarized in Supplementary Table 4. All 15 metabolites were significantly influenced by the two diets, while none of them was significantly influenced by the study periods. One unidentified metabolite (Unidentified_1) was subject to the interaction between diet and period.

Normalized abundances of metabolites discriminating for the high-fat vs. high-starch diet are presented in a heatmap in Figure 1. Clear clustering of the samples according to diets was observed (except for one sample HF(P1)3). Moreover, dogs fed the high-fat diet displayed a significantly higher abundance of 5 Non-annotated molecules, whereas dogs fed the high-starch diet displayed a significantly higher abundance of L-methionine, 6 molecules tentatively identified as (iso)leucyl-threonyl-valine; (iso)leucyl-(iso)valine or (iso)valyl-(iso)leucine; L-lysoprin or (iso)leucyl-serine/seryl-(iso)leucine or valyl-threonine or threonylin-valine; glycyl-valine or valyl-glycine or gly-norvaline or L-theanine or N-acetylorhithidine; valyl-valine; and (iso)leucyl-(iso)leucine, as well as 3 molecules putatively identified as spermic acid 2 or (iso)leucyl-threonoine or threonylin-(iso)leucine.

**DISCUSSION**

Most nutritional studies on the inflammatory response and metabolism in dogs have focused on the effects of protein (27, 42, 43). However, there is less information concerning dietary fat and nonfibrous carbohydrates, which are the main energy-delivering nutrients in traditional dog food (44). Health issues, particularly obesity-related problems, associated with diets rich in fat and starch, have received increasing attention in recent
TABLE 2 | Blood parameters (significant findings; n = 5).

| Item          | HS            | HF            | Period 1     | Period 2     | p value  |
|---------------|---------------|---------------|--------------|--------------|----------|
| GLU (µM)     | 78.40 ± 6.28  | 85.70 ± 5.21  | 83.10 ± 5.99 | 81.00 ± 7.60 | 0.054    |
| GLU/INS      | 16.25 ± 5.54  | 46.46 ± 59.15 | 45.24 ± 59.59| 17.48 ± 7.53 | 0.063    |
| Gly (µM)     | 190.1 ± 24.12 | 186.9 ± 37.32 | 201.0 ± 33.47| 176.0 ± 22.61| 0.094    |
| Ala (µM)     | 358.6 ± 118.5 | 239.5 ± 44.27 | 335.4 ± 129.1| 262.8 ± 66.54| 0.089    |
| NEFA (µM)    | 1.13 ± 0.25   | 0.94 ± 0.23   | 1.13 ± 0.31  | 0.95 ± 0.15  | 0.041    |
| GLU (µM)     | 85.11 ± 18.94 | 84.04 ± 16.98 | 80.64 ± 11.61| 88.51 ± 21.88| 0.139    |
| Tyr (µM)     | 54.87 ± 8.93  | 51.45 ± 10.59 | 53.82 ± 8.63 | 52.49 ± 11.09| 0.113    |

GLU, glucose; INS, insulin; Gly, glycine; Ala, alanine; NEFA, Non-esterified fatty acid; Phe, phenylalanine; Tyr, tyrosine.

TABLE 3 | Overview of characteristics of L-methionine, putatively annotated and unidentified metabolite markers.

| Compound n° | Putative identification* | ID level | Formula       | m/z       | ppm  | RT mode | Ionization score | VIP score | Reference |
|-------------|--------------------------|----------|---------------|-----------|------|---------|------------------|-----------|-----------|
| 1           | Unidentified_1           | –        |               | 223.1234  | 0.91 | H+      | 2.485            | –         |
| 2           | Unidentified_2           | –        |               | 415.2172  | 0.97 | H+      | 2.373            | –         |
| 3           | L-Methionine             | 1        | C₉H₁₁NO₂S     | 150.0580  | 2.04 | 1.57   | 2.996 HMDB        |           |
| 4           | Glycyl-Valine/Glycyl-Nonvaline/Valyl-Glycine/L-Theanine/N-acetylornithine | 4 | C₂₀H₁₄N₂O₃ | 173.0931  | 0.44 | 1.65   | 3.816 HMDB        |           |
| 5           | Unidentified_3           | –        |               | 356.1478  | 1.75 | H⁻      | 2.481            | –         |
| 6           | Spermic acid 2/[(iso)leucyl-threonine/Threoninyl-[(iso)leucine | 4 | C₁₀H₂₀N₂O₄ | 231.1357  | 2.72 | 2.22   | 2.321 HMDB        |           |
| 7           | L-Lysopine/[(iso)leucyl-serine/seryl-[(iso)leucine/Valyl-Threonine/Threonine/Valine | 4 | C₂₀H₁₄N₂O₃ | 219.1333  | 2.89 | 2.32   | 3.379 HMDB        |           |
| 8           | Valyl-valine             | 4        | C₁₀H₂₀N₂O₄ | 217.1542  | 2.34 | 4.24   | 3.160 HMDB        |           |
| 9           | Spermic acid 2/[(iso)leucyl-threonine/Threoninyl-[(iso)leucine | 4 | C₁₀H₂₀N₂O₄ | 231.1358  | 3.33 | 4.88   | 3.526 HMDB        |           |
| 10          | Spermic acid 2/[(iso)leucyl-threonine/Threoninyl-[(iso)leucine | 4 | C₁₀H₂₀N₂O₄ | 231.1357  | 3.03 | 5.16   | 4.124 HMDB        |           |
| 11          | [(iso)leucyl-valine/Valyl-[(iso)leucine | 4 | C₁₁H₂₂N₂O₅ | 229.1566  | 3.47 | 5.54   | 3.426 HMDB        |           |
| 12          | [iso)leucyl-Threonine/Valine | 4 | C₁₀H₂₀N₂O₄ | 332.2173  | 2.01 | 6.88   | 3.430 PubChem      |           |
| 13          | [iso)leucyl-[(iso)leucine | 4 | C₁₂H₂₄N₄O₅ | 243.1722  | 3.39 | 6.98   | 3.553 HMDB        |           |
| 14          | Unidentified_4           | –        |               | 283.1200  | 7.12 | H⁻      | 3.096            | –         |
| 15          | Unidentified_5           | –        |               | 263.0809  | 9.17 | H⁺      | 2.486            | –         |

*ID level, metabolite identification level according to Sumner et al. (41); ppm, absolute difference theoretical vs. detected m/z; RT, retention time (min.); VIP, variable importance in projection-score.

**IUPAC names are provided in Supplementary Table 5.**

Canine studies (14, 18, 45). For the first time, the present study investigated the inflammatory response and fecal metabolome in healthy lean dogs fed a high-fat or a high-starch diet.

No Effect on Inflammatory Related mRNA Expression

Obesity is characterized as a state of low-grade systemic inflammation, in which many inflammatory cytokines appear to play a role. They might also be linked to co-morbidities of obesity (46). Recent evidence suggests that a high-fat diet (60% fat) can induce obesity and exacerbate obesity-related inflammation and metabolic disorders in mice (47, 48). Moreover, gut inflammation is more severe in obesity-prone rats compared to obesity-resistant rats when both were fed a high-fat diet (45.3% fat) (49). Inflammation was also selectively more marked in the short-term high-fat-fed mice (60% fat) (50), which might depend on the level of weight gain. However, no significant changes were noted in the inflammatory related mRNA expression in this study. Overall, this result is not surprising as the dogs were fed to keep an ideal body condition and body weight. In fact, in our study, the two diets were isoenergetically exchanged, with the high-fat diet not exceeding the safe upper limit for dogs (70% for adult maintenance) (51). Next to this, except for the species differences and susceptibility to obesity, as genetically modified mice are more prone to developing morbid obesity (52), the discrepancy may be ascribed to the study's limited experimental duration, tested parameters or sample types. The study was not designed to investigate potential long-term effects. Tissue samples could not be collected, or more invasive parameters tested (e.g., inflammatory markers in fat or intestinal mucosal) in the dogs due to ethical reasons. Also, differences in the fat source and different levels of dietary fat intake between dogs and mice.
studies might also influence the experimental results. Therefore, future research investigations need to evaluate an extended set of inflammatory parameters under a variety of experimental conditions to unravel the inflammatory response of dogs fed a high-fat vs. a high-starch diet.

**Observed Metabolic Effects in Blood**

Vast differences were found in the metabolic profiles in blood our study. When dogs were fed with the high-fat diet, there is a tendency to increase glucose concentration and the ratio of glucose to insulin in the blood. This result suggests that the high-fat diet can affect glucose metabolism in healthy dogs. Previously, a high-starch diet (43% energy from starch and 26% from fat) has also been shown to increase glucose and insulin concentrations in healthy dogs compared to isoenergetic low-(12% energy from starch and 40% from fat) and moderate-starch diets (30% energy from starch and 34% from fat) (53). However, both fat and protein contents were adjusted to formulate the low- and moderate-starch diets, making it difficult to evaluate the effect of only fat in this study (53). Another study did not find any significantly changes in plasma glucose and insulin concentrations in dogs fed with a high-fat diet (63% energy from fat and 12% from starch) at two energetic intake levels (100% and 150% of maintenance energy requirements [MER]). Insulin sensitivity, however, was lower in the dogs of 150% MER group, which also had higher BW and BCS (15). The present study was not designed to analyse the effect on insulin sensitivity as only Pre-prandial samples were drawn. Thus, future research is needed to explore the possibility of such an effect. In the present study, the high-starch diet was associated with different metabolic effects compared to the high-fat diet in healthy lean dogs, as indicated by the increased NEFA concentration and a trend for increased Ala concentrations in the blood. Previous studies have reported that the increased Ala and NEFA levels are associated with increased glucose and lipid metabolism. Alanine is the key protein-derived gluconeogenic precursor, and plasma NEFA arise mainly from hydrolysis of triacylglycerol within the adipocyte (54, 55). This result suggests that compared to a high-fat diet, a high-starch intake could influence host glucose and lipid metabolism in healthy dogs. Future studies are needed to further investigate the metabolic effects of high-starch in exchange for high-fat diets.

**Observed Metabolic Effects in Feces**

Metabolomic research in dogs is still at a preliminary stage, with a limited number of published studies. Most of those studies focus on studying the metabolome in the context of disease or following dietary supplementation (56–59). However, the current study investigated shifts in the fecal metabolome of dogs on a high-starch vs. high-fat diet for the very first time. Polar metabolomics revealed a distinctively different fecal metabolomic profile in dogs fed a high starch vs. high fat diet. Specifically, the high-starch diet increased the abundance of L-methionine, and several molecules that were tentatively annotated as (iso)leucyl-threoninyl-valine, (iso)leucyl-(iso)valine/(iso)valyl-(iso)leucine, L-lysopine/(iso)leucyl-serine/seryl-(iso)leucine/valyl-threonine/threoninyl-valine, valyl-valine, (iso)leucyl-(iso)leucine, glycyl-valine/valyl-glycine/gly-norvaline/L-theanine/N-acetylornithine, and spermic acid 2/(iso)leucyl-threonine/threoninyl-(iso)leucine. Of the (putatively) annotated fecal metabolites, several are known to exert anti-oxidative and immunomodulatory effects. Methionine for example plays a critical role in the metabolism and health of many species, including dogs (60), as it is an essential amino acid involved in protein as well as aminoacyl-tRNA biosynthesis. Interestingly, there is accumulating evidence for aminoacyl-tRNA synthetases being involved in a wide range of physiological and pathological processes, including different types of immune responses (61). Recent research has furthermore
digested or intermediates in protein catabolism (6–13) were also putatively identified as di- or tripeptides. Di- or tripeptides are incomplete breakdown products of protein digestion or intermediates in protein catabolism (63), whilst recent studies furthermore reported that L-theanine supplement affects intestinal mucosal immunity by regulating SCFA metabolism in rats (64) and broilers (65). These studies implied that increased abundance of L-theanine in this study may have beneficial effects on intestinal reparation and immune. N-Acetylnorlithine is an intermediate in the enzymatic biosynthesis of the amino acid L-arginine from L-glutamate (66), which involves protein synthesis, anti-oxidative and immunomodulatory effects as well as e.g., improved mucosal barrier function (67).

Besides compound n° 4, eight other marker molecules (n° 6–13) were also putatively identified as di- or tripeptides. Di- or tripeptides are incomplete breakdown products of protein digestion or intermediates in protein catabolism (68).

For compounds n° 6, 9 and 10, alternative tentative annotations include spermic acid 2, and for compound n° 7, putative identification as L-lysopine is a possibility besides being a dipeptide. Spermic acid 2 is an metabolite of putrescine and spermine (https://contaminantdb.ca/contaminants/CHEM041097, ContaminantDB, McGill University, Canada), which are produced by the collective microbiome (69). Putrescine and spermine are required for several physiological functions including protein synthesis, cell growth and differentiation (70), and spermine is furthermore known to suppress inflammation (71). Increased spermic acid levels in this study thus implied the improvement of these roles by the high-starch diet. Regarding L-lysopine, a marker molecule with the same accurate mass was previously detected and putatively annotated in healthy suckling piglets (72). More specifically, the tentatively annotated L-lysopine was downregulated (p > 0.05) in piglet plasma following supplementation with an additional 0.12% methionine in the basal diet of sows during late gestation and lactation. Methionine supplementation showed a positive effect on piglet growth performance, which was hypothesized to be due to an increased antioxidant capacity of the piglets. This does not align with the proposed anti-oxidative effects of the high-starch vs. high-fat diet in this study since the putatively annotated L-lysopine molecule was higher following the intake of the high-starch vs. high-fat diet. According to HMDB, L-lysopine originates from food (or feed) (73), but there is very limited knowledge on spermic acid 2 and L-lysopine either dogs or any other species. Therefore, these findings warrant further investigation.

Five metabolite markers were upregulated following feeding of the high-fat diet compared to the high-starch diet. For compound n° 14 (“Unidentified_4”), a potential match with karalicin was retrieved in the PubChem database. There is however no existing prior knowledge about this compound either in any species, although it has been observed that it can be produced by certain bacteria (74). Another potential HMDB match for compound n° 14 is 2-Phenylethyl beta-D-glucopyranoside (C14H20O6). This compound has previously been detected in caraway and citrus (73), but it is unclear whether this compound could therefore also present in the dog feed. Due to these uncertainties, compound n° 14 was not annotated as either karalicin or 2-Phenylethyl beta-D-glucopyranoside. Overall, metabolite identification is a major bottleneck in metabolomics research (75), and even more so for studies in dogs since there is no existing dog metabolome database.

General Discussion
In summary, no difference was found in the inflammatory response in dogs fed with a high-starch vs. a high-fat diet, whereas different metabolic profiles were observed for the two diets. The high-starch diet in this study might be associated with several effects that indicated by the altered metabolic profiles, including protein biosynthesis, lipid metabolism, as well as exert anti-oxidation and/or immunomodulation. Future studies should encompass investigation of both short and long-term effects of high-starch in exchange for high-fat diets furthermore taking into account the source and level of fat intake. Moreover, in order to better understand the link between fecal metabolome and host metabolism, the analysis of microbiome is warranted in future studies, as well as multiple-omics analyses such as proteomics and lipidomics, which would enable studying the formation and/or degradation of proteins and the more a polar fraction of the metabolome. Lastly, it should be noted that Beagles in breeds are more prone to developing obesity (76) and therefore, follow-up studies should furthermore explore the effect of a high-fat vs. high-starch diet in relation to obesity and related problems, not only in Beagles, but also in other dog breeds, and in different age stages.

CONCLUSION
Inflammatory and metabolic responses of dogs fed a high-fat and high-starch diet were evaluated in the present study. The inflammatory response did not differ between the two diets. The high-starch diet was associated with increased blood NEFA level, a trend for increased blood Ala level and showed a profound impact on the fecal metabolic profile with alterations of the abundance of 15 fecal metabolites including methionine, the high-fat dietary intake was associated with a trend to for increase the glucose concentration, and the glucose/insulin ratio in the blood and significantly increase in the abundance of 5 other metabolites. These alterations might be linked to promotion of lipid metabolism, anti-oxidative effects, protein biosynthesis and catabolism, mucosal barrier function and immunomodulation in healthy dogs.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article can be found in online repositories (Figshare, doi: 10.6084/m9.figshare.17185376.v1).
ETHICS STATEMENT

The animal study was reviewed and approved by Ethical Committee of the Faculty of Veterinary Medicine, Ghent University, Belgium.

AUTHOR CONTRIBUTIONS

YL analyzed and interpreted the data and drafted the first version of the manuscript. DL performed the feeding trial and collected the samples. PN analyzed the proximate analysis. RH analyzed the S100A12 concentrations. VF analyzed fecal SCFA, BCFA, and NH3 concentrations. LH performed the metabolomic analysis and was a major contributor in writing the manuscript. MH was the project administration who conceived and designed the experiment. All authors read and approved the final manuscript.

REFERENCES

1. McGreevy PD, Thomson PC, Pride C, Fawcett A, Grassi T, Jones B. Prevalence of obesity in dogs examined by Australian veterinary practices and the risk factors involved. *Vet Rec.* (2005) 156:695–702. doi: 10.1136/vr.156.22.695
2. Lund EM, Armstrong PJ, Kirk CA, Klauser JS. Prevalence and risk factors for obesity in adult dogs from private US veterinary practices. *Int J Appl Vet Res Med.* (2006) 4:177.
3. Diez M, Picavet P, Ricci R, Dequenne M, Renard M, Bongartz A, et al. Health screening to identify opportunities to improve preventive medicine in cats and dogs. *J Small Anim Pract.* (2015) 56:463–9. doi: 10.1111/j sap.12365
4. German AJ, Holden SL, Wiseman-Orr ML, Reid J, Nolan AM, Biourge V, et al. Quality of life is reduced in obese dogs but improves after successful weight loss. *Vet J.* (2012) 192:248–34. doi: 10.1016/j.tvjl.2011.09.015
5. Kealy RD, Lawler DF, Ballam JM, Mantz SL, Biery DN, Greeley EH, et al. Effects of diet restriction on life span and age-related changes in dogs. *J Vet Med Assoc.* (2002) 220:1315–20. doi: 10.2460/jvma.2002.220.1315
6. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. *J Intern Med.* (2007) 262:468–14. doi: 10.1111/j.1365-2796.2007.01852.x
7. Freeman LM, Laffamme DP, Michel KE. Comparison of adipokine concentrations and markers of inflammation in obese versus lean dogs. *Intern J Appl Vet Res Med.* (2009) 7:196–205.
8. Rafaj RB, Kules J, Marinculic A, Tvarijonaviciute A, Ceron J, Mihaljevic Z, et al. Plasma markers of inflammation and hemostatic and endothelial activity in naturally overweight and obese dogs. *IMC Vet Res.* (2016) 13:13. doi: 10.1186/s12917-016-0929-8
9. Hill JO, Melanson EL, Wyatt HT. Dietary fat intake and regulation of energy balance: implications for obesity. *J Nutr.* (2000) 130:2845–85. doi: 10.1093/jn/130.2.2845
10. French S, Robinson T. Fats and food intake. *Curr Opin Clin Nutr Metab Care.* (2003) 6:629–34. doi: 10.1097/00075197-200311000-00004
11. George V, Tremblay A, Després JP, Leblanc C, Bouchard C. Effect of dietary fat content on total and regional adiposity in men and women. *Int J Obes.* (1990) 14:1085–94.
12. Tucker LA, Kano MJ. Dietary fat and body fat: a multivariate study of 205 adult females. *Am J Clin Nutr.* (1992) 56:616–22. doi: 10.1093/ajcn/56.4.616
13. Parks BW, Nam E, Org E, Kostem E, Norheim E, Hui ST, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. *Cell Metab.* (2013) 17:141–152. doi: 10.1016/j.cmet.2012.12.007
14. Kaiyala KJ, Pigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. *Diabetes.* (2000) 49:1525–33. doi: 10.2337/diabetes.49.9.1525
15. Moinard A, Payen C, Ouguerram K, Andre A, Hernandez J, Drut A, et al. Effects of high-fat diet at two energetic levels on fecal microbiota, colonic barrier, and metabolic parameters in dogs. *Front Vet Sci.* (2020) 7:566282. doi: 10.3389/fvets.2020.566282
16. Cotillard A, Kennedy SP, Kong LC, Prifiti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbiota gene richness. *Nature.* (2013) 500:585–8. doi: 10.1038/nature12480
17. Rocchini AP, Marker P, Cervenka T. Time course of insulin resistance associated with feeding dogs a high-fat diet. *Am J Physiol Endocrinol Metab.* (1997) 272:E147–54. doi: 10.1152/ajpendo.1997.272.1.E147
18. Schauf S, de la Fuente G, Newbold CJ, Salas-Mani A, Torre C, Abeica L, et al. Effect of dietary fat to starch content on fecal microbiota composition and activity in dogs. *J Anim Sci.* (2018) 96:3684–98. doi: 10.1093/jas/sky264
19. Svilhus B, Hervik AK. Digestion and metabolic fates of starch, and its relation to major nutrition–related health problems: a review. *Starch-Starke.* (2016) 68:302–13. doi: 10.1002/star.201500295
20. Rankovic A, Adolphe JL, Verbrougge A. Role of carbohydrates in the health of dogs. *J Am Vet Med Assoc.* (2019) 255:554–54. doi: 10.2460/jvma.255.5.546
21. Riccardi G, Clemente G, Giacco R. Glycemic index of local foods of the S100A12 concentrations. VF analyzed fecal SCFA, BCFA, and NH3 concentrations. LH performed the metabolomic analysis and was a major contributor in writing the manuscript. MH was the project administration who conceived and designed the experiment. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Morris Animal Foundation (D13CA-405).

ACKNOWLEDGMENTS

The authors would like to thank Daniel Tensy, Amy Deluycker, Beata Pomian, Ellen De Paepe and Marta Lourenco for technical assistance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2022.801863/full#supplementary-material
products: interlaboratory study. J Assoc Off Anal Chem. (1988) 71:1017–23. doi: 10.1093/jaoac/71.5.1017
30. German A., Hervera M., Hunter L., Holden S., Morris P., Biourge V., et al. Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domest Anim Endocrinol. (2009) 37:214–26. doi: 10.1016/j.drom.2009.07.001
31. Vreken P., van Lint A., Bootsma A., Overmars H., Wanders R., van Gennip A. Rapid diagnosis of organic acidaemias and fatty-acid oxidation defects by quantitative electrospray tandem-MS acyl carnitine analysis in plasma. Adv Exp Med Biol. (1999) 466:327–37. doi: 10.1007/0-306-46818-2_38
32. Rizzo C., Boenzi S., Wanders R., Duran M., Caruso U., Dionisio-Vici C. Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. Pediatr Res. (2003) 53:1013–8. doi: 10.1203/01.PDR.0000064902.59052.0F
33. Heilman RM., Cranford SM., Ambrus A., Grutzner N., Schellenberg S., Ruaux CG., et al. Validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of canine S100A12. Vet Clin Pathol. (2016) 45:135–47. doi: 10.1111/vcp.12320
34. Castro-Montoya J., de Campeneere S., van Ranst G., Fievez V. Interactions between methane mitigation additives and basal substrates on in vitro methane and VFA production. Anim Feed Sci Technol. (2012) 176:47–60. doi: 10.1016/j.ift.2012.07.007
35. Chaney AL., Marbach EP. Modified reagents for determination of urea and ammonia. Clin Chem. (1962) 8:130–2. doi: 10.1093/clinchem/8.2.130
36. Peters IR., Helps CR., Calvert EL., Hall EJ. Identification of four methane mitigation additives and basal substrates on in vitro methane and VFA production. Anim Feed Sci Technol. (2008) 142:1228–37. doi: 10.1016/j.anifeedsci.2007.10.013
37. Mercier E., Peters IR., Day MJ. Clcrx C., Peeters D. Toll-and NOD-like receptor mRNA expression in canine sino-nasal aspergillosis and idiopathic lymphoplasmacytic rhinitis. Vet Immunol Immunopathol. (2015) 165:618–24. doi: 10.1016/j.vetimm.2012.01.009
38. Vandesempele J., de Preter K., Pattyn F., Poppe B., van Roy N., de Paepe E. A validated multi-matrix platform for metabolomic fingerprinting of the human gut phenotype. Anal. Chem. (2015) 87:10927–10934. doi: 10.1021/acs.analchem.5b02688
39. de Paepe E., van Meulebroek L., Rombouts C., Huysman S., Verplanken K., Lapauw B., et al. A validated multi-matrix platform for metabolomic fingerprinting of the human gut phenotype. Anal. Chem. (2015) 87:10927–10934. doi: 10.1021/acs.analchem.5b02688
40. Jun Y., Ren W., Yang G., Duan J., Huang X., Fang R., et al. L-Cysteine affects intestinal mucosal immunity by regulating short-chain fatty acid metabolism under dietary fiber feeding. J Sci Food Agric. (2020) 110:1718–25. doi: 10.1002/jsfa.10192
41. Caldovic I., Tuchman M. N-acetylglutamate and its changing role through evolution. Biochem J. (2003) 372:279–90. doi: 10.1042/BJ20030502
42. Newsholme P., Procopio J., Lima MMR., Pitton-Curi TC., Curi R. Glutamine and glutamate-their central role in cell metabolism and function. Cell Biochem Funct. (2003) 21:1–9. doi: 10.1080/07001070390179713.
68. Dallas DC, Sanctuary MR, Qu Y, Khajavi SH, van Zandt AE, Dyandra M, et al. Personalizing protein nourishment. Crit Rev Food Sci Nutr. (2017) 57:3313–31. doi: 10.1080/10408398.2015.1117412
69. Nakamura A, Ooga T, Matsumoto M. Intestinal luminal putrescine is produced by collective biosynthetic pathways of the commensal microbiome. Gut Microbes. (2019) 10:159–71. doi: 10.1080/19490076.2018.1494466
70. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. (2009) 61:880–94 doi: 10.1002/iub.230
71. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med. (1997) 185:1759–68 doi: 10.1084/jem.185.10.1759
72. Azad MAK, Bin P, Liu G, Fang J, Li T, Yin Y. Effects of different methionine levels on offspring piglets during late gestation and lactation. Food Funct. (2018) 9:5843–54. doi: 10.1039/C8FO01343H
73. Yannai S. Dictionary of food compounds with CD-ROM. In: Additives, Flavors, and Ingredients. New York, NY: CRC Press (2003).
74. Lampis G, Deidda D, Maullu C, Petruzzelli S, Pompei R, Monache FD, et al. Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida I Production, isolation, physico-chemical properties and structure elucidation. J Antibiot. (1996) 49:260–2. doi: 10.7164/antibiotics.49.260
75. Ulaszewska M, Weinert CH, Trimigno A, Portmann R, Andres Lacueva C, Badertscher R, et al. Nutrismetabolomics: an integrative action for metabolomic analyses in human nutritional studies. Mol Nutr Food Res. (2019) 63:1800384. doi: 10.1002/mnfr.201970001
76. Bland IM, Guthrie-Jones A, Taylor RD, Hill J. Dog obesity: owner attitudes and behaviour. Prev Vet Med. (2009) 92:333–40. doi: 10.1016/j.prevetmed.2009.08.016

Conflict of Interest: IP was employed by the company SYNLAB VPG.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lyu, Liu, Nguyen, Peters, Heilmann, Fievez, Hemeryck and Hesta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.